Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Endocrine journal

• Publication date

  2009-11-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1507/ENDOCRJ.K09E-147PMID 19706990
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes.

  2009cited by this paper
• Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

  2009cited by this paper
• Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Mellitus

  2008cited by this paper
• Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes

  2008cited by this paper
• Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.

  2008cited by this paper
• The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes

  2007cited by this paper
• New technologies and therapies in the management of diabetes.

  2007cited by this paper
• Combating diabetes and obesity in Japan

  2006cited by this paper
• Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.

  2006cited by this paper
• Diabetes in Japan

  2005cited by this paper
• Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.

  2005cited by this paper
• Day-long Subcutaneous Infusion of Exenatide Lowers Glycemia in Patients with Type 2 Diabetes

  2005cited by this paper
• Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations.

  2005cited by this paper
• Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

  2005cited by this paper
• Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.

  2004cited by this paper
• Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.

  2004cited by this paper
• Effectiveness of progressive dose‐escalation of exenatide (exendin‐4) in reducing dose‐limiting side effects in subjects with type 2 diabetes

  2004cited by this paper
• Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.

  2003cited by this paper
• Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

  2003cited by this paper
• Enhancing incretin action for the treatment of type 2 diabetes.

  2003cited by this paper
• Diabetes trends in Japan

  2002cited by this paper
• Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group.

  2000cited by this paper
• Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria

  1999cited by this paper
• Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe.

  1999cited by this paper
• Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria

  1999cited by this paper
• Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

  1999cited by this paper
• Descriptive epidemiology of body mass index in Japanese adults in a representative sample from the National Nutrition Survey 1990–1994

  1998cited by this paper
• UKPDS 26: sulphonylurea failure in non‐insulin‐dependent diabetic patients over six years

  1998cited by this paper
• Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy.

  1995cited by this paper
• Secondary failure of oral hypoglycaemic agents: frequency, possible causes, and management.

  1994cited by this paper

• G protein-coupled receptors driven intestinal glucagon-like peptide-1 reprogramming for obesity: Hope or hype?

  2024cites this paper
• A REVIEW ON RECENT ADVANCES IN THE TREATMENT OF DIABETES MELLITUS.

  2022cites this paper
• Gastrointestinal adverse events with insulin glargine/lixisenatide fixed‐ratio combination versus glucagon‐like peptide‐1 receptor agonists in people with type 2 diabetes mellitus: A network meta‐analysis

  2020cites this paper
• Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials

  2019cites this paper
• The efficacy and safety of exenatide once weekly in patients with type 2 diabetes

  2019cites this paper
• Changes in Heart Rate Associated with Exenatide Once Weekly: Pooled Analysis of Clinical Data in Patients with Type 2 Diabetes

  2018cites this paper
• Safety, tolerability and efficacy of lixisenatide as monotherapy in Japanese patients with type 2 diabetes mellitus: An open‐label, multicenter study

  2017cites this paper
• A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes

  2017influential citation
• Exenatide: pharmacokinetics, clinical use, and future directions

  2017cites this paper
• Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom

  2017cites this paper
• Exenatide Once Weekly: A Review of Pharmacology and Treatment Considerations in Type 2 Diabetes.

  2016cites this paper
• Onset of Glycemic and Weight Outcomes in Patients Initiating Exenatide Once Weekly: The Relationship of Exenatide Exposure with Efficacy over the First 24 Weeks of Treatment

  2016cites this paper
• Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

  2016cites this paper
• 持続性エキセナチド注射剤 ビデュリオン ® 皮下注用2mgペン

  2016cites this paper
• Early Pharmacodynamic Effects of Exenatide Once Weekly in Type 2 Diabetes Are Independent of Weight Loss: A Pooled Analysis of Patient-level Data.

  2016cites this paper
• Exenatide once weekly improved 24‐hour glucose control and reduced glycaemic variability in metformin‐treated participants with type 2 diabetes: a randomized, placebo‐controlled trial

  2016cites this paper
• Target-mediated pharmacokinetic/pharmacodynamic model based meta-analysis and dosing regimen optimization of a long-acting release formulation of exenatide in patients with type 2 diabetes mellitus.

  2015cites this paper
• Pharmacokinetics and pharmacodynamics of a polyethylene glycol (PEG)‐conjugated GLP‐receptor agonist once weekly in Chinese patients with type 2 diabetes

  2015cites this paper
• Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus

  2015cites this paper
• Effects of the glucagon-like peptide-1 (GLP-1) analogues exenatide, exenatide extended-release, and of the dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin on glucose metabolism in healthy cats.

  2015cites this paper
• Exenatide as a potential treatment for patients with Parkinson's disease: First steps into the clinic

  2014cites this paper
• Optimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor Agonists

  2014cites this paper
• [A case of an elderly diabetic patient with dementia effectively treated with weekly exenatide].

  2014cites this paper
• Pharmacokinetics, safety, and tolerability of single‐ and multiple‐dose exenatide once weekly in Chinese patients with type 2 diabetes mellitus (对中国2型糖尿病患者单次和多次给予艾塞那肽周制剂的药代动力学、安全性和耐受性研究)

  2013influential citation
• Exenatide extended-release; clinical trials, patient preference, and economic considerations

  2013cites this paper
• Hydrogel drug delivery system with predictable and tunable drug release and degradation rates

  2013influential citation
• Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.

  2013cites this paper
• Individualizing care with injectable glucose-lowering agents.

  2013cites this paper
• Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus

  2012cites this paper
• Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study.

  2012cites this paper
• Exenatide Extended-Release Injection

  2012cites this paper
• Clinical Efficacy and Safety of Once-Weekly Glucagon-Like Peptide-1 Agonists in Development for Treatment of Type 2 Diabetes Mellitus in Adults

  2012cites this paper
• Exenatide Extended-Release

  2012cites this paper
• Degradable Polymeric Carriers for Parenteral Controlled Drug Delivery

  2012cites this paper
• Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.

  2011cites this paper
• The efficacy and tolerability of exenatide in comparison to placebo; a systematic review and meta-analysis of randomized clinical trials.

  2011cites this paper
• Management of type 2 diabetes: new and future developments in treatment.

  2011cites this paper
• Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials

  2011influential citation
• The Current Status of Exenatide Once Weekly

  2011cites this paper
• Exenatide: Review of its Role as Adjunctive Therapy in Patients with Type 2 Diabetes

  2011cites this paper
• Exenatide once weekly in type 2 diabetes mellitus

  2011cites this paper
• Exenatide once weekly: clinical outcomes and patient satisfaction

  2010influential citation
• Incretin-based therapy and type 2 diabetes.

  2010cites this paper
• Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review

  2010cites this paper
• Incretin-based therapies for type 2 diabetes mellitus in Asian patients: Analysis of clinical trials

  2010cites this paper
• Treatment of diabetes with glucagon-like peptide-1 gene therapy

  2010cites this paper
• Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review

  2010cites this paper
• exenatide once weekly: clinical outcomes and patient satisfaction

  2010influential citation
• Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide?

  2010influential citation
• TYP-2-Diabetes

  2007cites this paper